

Phase I and pharmacologic studies of pyrazoloacridine,
on single-dosing and multiple-dosing schedules.

Journal of Clinical Oncology

13, 1975-1984

DOI: [10.1200/jco.1995.13.8.1975](https://doi.org/10.1200/jco.1995.13.8.1975)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. <i>Biochemical Pharmacology</i> , 1996, 51, 1649-1659.	2.0	23
2	Phase I trial design: Are new methodologies being put into practice?. <i>Annals of Oncology</i> , 1996, 7, 561-566.	0.6	59
3	Status of new anthrapyrazole and pyrazoloacridine derivatives. <i>Critical Reviews in Oncology/Hematology</i> , 1996, 22, 79-87.	2.0	10
4	Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140). <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 453-458.	1.1	8
5	Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. <i>British Journal of Cancer</i> , 1997, 75, 878-883.	2.9	28
6	Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 225-227.	1.1	17
7	Determination of the anticancer agent CI-980 in plasma by achiral liquid chromatography on a Pirkle-type stationary phase. <i>Biomedical Applications</i> , 1997, 693, 493-497.	1.7	1
8	Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. <i>Investigational New Drugs</i> , 1998, 16, 93-96.	1.2	13
9	A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1998, 16, 337-340.	1.2	4
10	Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.. <i>Journal of Clinical Oncology</i> , 1998, 16, 181-186.	0.8	15
11	Current status of pyrazoloacridine as an anticancer agent. , 1999, 17, 43-48.		33
12	Phase II Trial of Pyrazoloacridine in Children With Solid Tumors: A Pediatric Oncology Group Phase II Study. <i>The American Journal of Pediatric Hematology/oncology</i> , 2000, 22, 506-509.	1.3	18
13	Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000, 18, 265-267.	1.2	8
14	Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. <i>Investigational New Drugs</i> , 2000, 18, 247-251.	1.2	19
15	Dual topoisomerase I/II inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2000, 6, 92-108.	0.5	19
16	Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2001, 19, 327-328.	1.2	5
17	A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 151-154.	1.1	8
18	Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2002, 84, 32-35.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Phase II Trial of Pyrazoloacridine in Patients with Persistent or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2002, 84, 241-244.	0.6	19
20	A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. <i>Investigational New Drugs</i> , 2002, 20, 297-304.	1.2	5
21	A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. <i>Investigational New Drugs</i> , 2003, 21, 75-84.	1.2	7
22	Dual Topoisomerase I / II Inhibitors in Cancer Therapy. <i>Current Topics in Medicinal Chemistry</i> , 2003, 3, 339-353.	1.0	136
23	Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide, and Topotecan in Drug-Resistant Tumor Cells. <i>Clinical Cancer Research</i> , 2004, 10, 1160-1169.	3.2	7
24	The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes. <i>Clinical Cancer Research</i> , 2004, 10, 1471-1480.	3.2	29
25	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial. <i>Investigational New Drugs</i> , 2005, 23, 495-503.	1.2	20
26	Treatment of Relapsed and Refractory Neuroblastoma. , 2005, , 193-211.		1
27	Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 6568-6578.	3.2	55
28	Neurologic Complications of Chemotherapy. , 2008, , 287-326.		9
29	Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. <i>Investigational New Drugs</i> , 2011, 29, 347-351.	1.2	19
30	Neurological complications of chemotherapy to the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 903-916.	1.0	54
31	Central Nervous System Complications of Cancer Therapy. , 2003, , 215-231.		16
32	Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32.. <i>Journal of Clinical Investigation</i> , 1996, 98, 2588-2596.	3.9	62
34	Central Neurotoxicity of Chemotherapy. , 2023, , 1-27.		0
35	Central Neurotoxicity of Chemotherapy. , 2023, , 1-27.		0